These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34077286)

  • 1. Does Cefiderocol Have a Potential Role in Cystic Fibrosis Pulmonary Exacerbation Management?
    Gavioli EM; Guardado N; Haniff F; Deiab N; Vider E
    Microb Drug Resist; 2021 Dec; 27(12):1726-1732. PubMed ID: 34077286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.
    Gramegna A; Millar BC; Blasi F; Elborn JS; Downey DG; Moore JE
    J Glob Antimicrob Resist; 2018 Sep; 14():224-227. PubMed ID: 29559421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
    Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
    Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis.
    Tunney MM; Elborn JS; McLaughlin CS; Longshaw CM
    J Glob Antimicrob Resist; 2024 Mar; 36():407-410. PubMed ID: 38336228
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.
    Conway SP; Brownlee KG; Denton M; Peckham DG
    Am J Respir Med; 2003; 2(4):321-32. PubMed ID: 14719998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains.
    Jean-Pierre V; Sorlin P; Pantel A; Chiron R; Lavigne JP; Jeannot K; Marchandin H;
    Ann Clin Microbiol Antimicrob; 2024 Jun; 23(1):54. PubMed ID: 38886694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefiderocol: A Siderophore Cephalosporin.
    El-Lababidi RM; Rizk JG
    Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
    Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
    Lee YR; Yeo S
    Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation.
    Lobo LJ; Tulu Z; Aris RM; Noone PG
    Transplantation; 2015 Oct; 99(10):2196-202. PubMed ID: 25856407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Perspectives on Antimicrobial Agents: Cefiderocol.
    McCreary EK; Heil EL; Tamma PD
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0217120. PubMed ID: 34031052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.
    Monogue ML; Tsuji M; Yamano Y; Echols R; Nicolau DP
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal.
    Gijón D; García-Castillo J; Fernández-López MC; Bou G; Siller M; Calvo-Montes J; Pitart C; Vila J; Torno N; Gimeno C; Cruz H; Ramos H; Mulet X; Oliver A; Ruiz-Garbajosa P; Canton R
    Rev Esp Quimioter; 2024 Feb; 37(1):69-77. PubMed ID: 37882320
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Grohs P; Taieb G; Morand P; Kaibi I; Podglajen I; Lavollay M; Mainardi JL; Compain F
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of antibiotics for cystic fibrosis pulmonary exacerbations due to highly resistant nonlactose fermenting Gram negative bacilli: Meropenem-vaborbactam and cefiderocol.
    Belcher R; Zobell JT
    Pediatr Pulmonol; 2021 Sep; 56(9):3059-3061. PubMed ID: 34215020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
    Saiman L; Chen Y; Gabriel PS; Knirsch C
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1105-7. PubMed ID: 11897598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of S-(3,4-dichlorobenzyl)isothiourea hydrochloride and novel structurally related compounds against multidrug-resistant bacteria, including Pseudomonas aeruginosa and Burkholderia cepacia complex.
    Nicholson A; Perry JD; James AL; Stanforth SP; Carnell S; Wilkinson K; Anjam Khan CM; De Soyza A; Gould FK
    Int J Antimicrob Agents; 2012 Jan; 39(1):27-32. PubMed ID: 21993484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.